MONTGOMERYVILLE, Pa., Nov. 1 /PRNewswire-FirstCall/ -- PhotoMedex, Inc.
(Nasdaq: PHMD) announced today that it is scheduled to make an investor
presentation at the Rodman & Renshaw 8th Annual Healthcare Conference at
9:10 a.m. EST on Monday, November 6, 2006. The conference is being held at
the New York Palace Hotel, 455 Madison Avenue, (between 50th and 51st
Streets) New York, NY.
A live webcast of the Company's presentation at the Conference will be
available by going to www.photomedex.com and clicking on the link to
Investor Relations. An archived replay will be available for a period of 90
days.
About PhotoMedex
PhotoMedex is engaged in the development of proprietary excimer laser
and fiber optic systems and techniques directed toward dermatological
applications, with FDA 510(k) clearances to market the XTRAC(R) laser
system for the treatment of psoriasis, vitiligo, atopic dermatitis and
leukoderma. In addition, the Company provides contract medical procedures
to hospitals, surgi-centers and doctors' offices, offering a wide range of
products and services across multiple specialty areas, including
dermatology, urology, gynecology, orthopedics, and other surgical
specialties. The Company is a leader in the development, manufacturing and
marketing of medical laser products and services. In addition, as a result
of the merger with ProCyte, PhotoMedex now develops and markets products
based on its patented, clinically proven Copper Peptide technology for skin
health, hair care and wound care. PhotoMedex sells directly to
dermatologists, plastic and cosmetic surgeons, spas and salons and through
licenses with strategic partners into the consumer market, including a
long-term worldwide license agreement with Neutrogena(R), a Johnson &
Johnson company. ProCyte brands include Neova(R), Ti-Silc(R),
VitalCopper(R), Simple Solutions(R) and AquaSante(R).
SAFE HARBOR STATEMENT
Some paragraphs of this press release, particularly those describing
PhotoMedex' strategies, contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1993, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. While
PhotoMedex is working to achieve those goals and strategies, actual results
could differ materially from those projected in the forward-looking
statements as a result of a number of factors, including difficulties in
marketing its products and services, need for capital, competition from
other companies and other factors, any of which could have an adverse
effect on the business plans of PhotoMedex, its reputation in the industry
or its expected financial return from operations. Factors such as these
could have an adverse effect on PhotoMedex' results of operations. In light
of significant uncertainties inherent in forward-looking statements
included herein, the inclusion of such statements should not be regarded as
a representation by PhotoMedex and its subsidiaries that they will achieve
such forward-looking statements.
Contacts: Allen & Caron PhotoMedex, Inc.
Matt Clawson (investors) Dennis McGrath, CFO
949-474-4300 215-619-3287
matt@allencaron.cominfo@photomedex.com

SOURCE PhotoMedex, Inc.

MONTGOMERYVILLE, Pa., Nov. 1 /PRNewswire-FirstCall/ -- PhotoMedex, Inc.
(Nasdaq: PHMD) announced today that it is scheduled to make an investor
presentation at the Rodman & Renshaw 8th Annual Healthcare Conference at
9:10 a.m. EST on Monday, November 6, 2006. The conference is being held at
the New York Palace Hotel, 455 Madison Avenue, (between 50th and 51st
Streets) New York, NY.
A live webcast of the Company's presentation at the Conference will be
available by going to www.photomedex.com and clicking on the link to
Investor Relations. An archived replay will be available for a period of 90
days.
About PhotoMedex
PhotoMedex is engaged in the development of proprietary excimer laser
and fiber optic systems and techniques directed toward dermatological
applications, with FDA 510(k) clearances to market the XTRAC(R) laser
system for the treatment of psoriasis, vitiligo, atopic dermatitis and
leukoderma. In addition, the Company provides contract medical procedures
to hospitals, surgi-centers and doctors' offices, offering a wide range of
products and services across multiple specialty areas, including
dermatology, urology, gynecology, orthopedics, and other surgical
specialties. The Company is a leader in the development, manufacturing and
marketing of medical laser products and services. In addition, as a result
of the merger with ProCyte, PhotoMedex now develops and markets products
based on its patented, clinically proven Copper Peptide technology for skin
health, hair care and wound care. PhotoMedex sells directly to
dermatologists, plastic and cosmetic surgeons, spas and salons and through
licenses with strategic partners into the consumer market, including a
long-term worldwide license agreement with Neutrogena(R), a Johnson &
Johnson company. ProCyte brands include Neova(R), Ti-Silc(R),
VitalCopper(R), Simple Solutions(R) and AquaSante(R).
SAFE HARBOR STATEMENT
Some paragraphs of this press release, particularly those describing
PhotoMedex' strategies, contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1993, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. While
PhotoMedex is working to achieve those goals and strategies, actual results
could differ materially from those projected in the forward-looking
statements as a result of a number of factors, including difficulties in
marketing its products and services, need for capital, competition from
other companies and other factors, any of which could have an adverse
effect on the business plans of PhotoMedex, its reputation in the industry
or its expected financial return from operations. Factors such as these
could have an adverse effect on PhotoMedex' results of operations. In light
of significant uncertainties inherent in forward-looking statements
included herein, the inclusion of such statements should not be regarded as
a representation by PhotoMedex and its subsidiaries that they will achieve
such forward-looking statements.
Contacts: Allen & Caron PhotoMedex, Inc.
Matt Clawson (investors) Dennis McGrath, CFO
949-474-4300 215-619-3287
matt@allencaron.cominfo@photomedex.com
SOURCE PhotoMedex, Inc.